Find A Clinical Trial

Disease Type: Solid Tumors All

Trial ID TSC-007
Sponsor ID PRECISION-1

A Phase 2 multi-center open-label basket trial of ABI-009 (nab-sirolimus) for adult and adolescent patients with solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes

Trial ID 516-014
Sponsor ID Mirati

A Multicenter, Open-Label, Extension Study of the Safety and Tolerability of Sitravatinib Alone or in Combination with Other Anticancer Therapies in Patients with Advanced or Metastatic Solid Malignancies

Trial ID JBI-802-101
Sponsor ID Jubilant Therapeutics

A First-in-Human, Open-Label, Dose Escalation and Expansion Study of Orally Administered JBI-802 in Patients with Advanced Solid Tumors

Trial ID ASP3082
Sponsor ID Astellas

A Phase I Study of ASP3082 in Participants with Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies with KRAS G12D

Trial ID SGN-ALPV-001
Sponsor ID Seagen

A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors

Trial ID ALKS 4230-003
Sponsor ID ARTISTRY-3

Clinical and Immunologic Activity of Nemvaleukin Alfa With a Less Frequent IV Dosing Schedule as Monotherapy and in Combination with Pembrolizumab and Impact on Tumor Microenvironment in Solid Tumor Patients (ARTISTRY-3)

Trial ID RMC-6291-001
Sponsor ID Revolution Medicines

Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRAS G12C Mutant Solid Tumors

Trial ID IO-202-CL-002
Sponsor ID Immune-Onc Therapeutics

A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose Expansion Study of IO-202 in Combination with Pembrolizumab in Subjects with Advanced, Relapsed, or Refractory Solid Tumors

Trial ID ASN004
Sponsor ID Asana BioSciences

An Open Label, Multicenter, Dose-Finding Clinical Phase 1 Study of ASN004 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy with Advanced Malignant Solid Tumors.

Trial ID XTX101
Sponsor ID Xilio Development

A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX101 Monotherapy and XTX101 and Pembrolizumab Combination Therapy in Patients with Advanced Solid Tumors.